No Permanent Implant

The Senella® Scaffolds will be formed out of a biocompatible and absorbable polymer that is FDA-approved and CE-marked for a variety of other clinical applications. Multiple Preclinical Studies have shown that the scaffolds slowly get absorbed by the body while the patient's own tissue forms synchronously. After the scaffold has been fully resorbed, the preclinical trials show that the end-result is natural breast tissue with no foreign body remnants.

Degradation Behaviour of BellaSeno implants

Natural Tissue

Our Scaffolds will aim to guide the growth of natural tissue with the use of patient's own body fat harvested via routinely practiced liposuction procedure.

Anticipated Key Benefits:

  • Tissue is regenerated from the patient's own body-fat, without the use of isolated/cultivated stem cells or animal-derived products - may help avoid risk of rejection, chronic infection and capsular contracture associated with current standard of care.
  • No foreign material is permanently implanted in the body, so long-term medication may no longer be needed.
  • Risk of repeated surgeries may be reduced.

Fat Injection

Interested in transforming your Additive Manufacturing using our technology?

BellaMake by BellaSeno offers the use of Design and Additive Manufacturing expertise of BellaSeno's breakthrough Senella® technology platform to create:

  1. A wide spectrum of 3D Cell Culture Meshes and Custom Scaffolds for drug screening and research use.
  2. CMO services for medical devices.

These services can be used for:

  • Tissue Engineering and Cancer Research.
  • Medical Device Manufacturing.
  • Drug Screening

Project Concept


The Senella® technology is a product of more than 5 years of rigorous product development and preclinical studies. Publications cited below refer to the Biocompatibility and Efficacy of Senella® devices within Preclinical Studies

Our Founding and Management Team

BellaSeno Founding and Management team comprises experts from diverse fields ranging from biomedical engineering, Additive Manufacturing, Plastic Surgery, Medical Imaging and Polymer Development.

Simon Champ, PhD, MBA
Chief Executive Officer

Simon Champ, PhD

Dr. Champ has held a variety of management positions in R&D, marketing and business development in the chemical industry. Dr. Champ’s MBA thesis focused on the commercialisation of regenerative medicine technologies. Dr. Champ is co-founder of Progensis UG (haftungsbeschränkt), a boutique consultancy focusing on the regenerative medicine industry. BellaSeno benefits from Dr. Champ’s experience in business strategy, marketing and venture valuation, as well as his international network of commercially relevant contacts.

Mohit P. Chhaya, PhD
Chief Technology Officer

Mohit P Chhaya, PhD

Dr. Chhaya is an Expert in Biomedical Engineering and Additive Manufacturing Technologies and is one of the Key Contributors in the development of BellaSeno's Technology Platform.

In his role as CTO, Dr. Chhaya led the growth and development of the company and additive manufacturing processes from initial conception to full ISO 13485 certification

Prior to BellaSeno, Dr. Chhaya worked as a Post-Doctoral Researcher at Technical University of Munich (TUM) - where he was part of a team that got awarded an Exist Research Translation grant by the German government. As part of duties, Dr. Chhaya shaped the global regulatory strategy for innovative scaffolds for lymph-node regeneration. Dr. Chhaya also regularly gives short lectures on Research Translation at the TUM Tissue Engineering and Regenerative Medicine Course aimed at clinicians.

Dr. Chhaya's PhD thesis was focused on the design and manufacturing of the breast implants used by BellaSeno - for which he was the recipient of university-wide Best Thesis Award (2015). From a translational point of view, the project led to a licensing deal with a major Bioprinter manufacturer, two international patent applications (EP 14 200 090.0 and EP 14 184 126.2) and two spinoff companies (BellaSeno GmBH and Biofabrication Design Solutions Pty Ltd).

Prior to undertaking his PhD, Dr. Chhaya worked as a Data Analyst at Moody’s Analytics for 2.5 years and, during his university years, was a co-founder of 2 student-run start-ups in the fields of marketing and innovation consultancy. One of Dr. Chhaya’s start-ups was awarded the runners-up prize in national Young Achievement Australia awards.

Dietmar W. Hutmacher, PhD, MBA
Supervisory Board Member

DProf Dietmar W. Hutmacher, PhD, MBA

Distinguished Prof Hutmacher is a biomedical engineer, an educator, an inventor, and a creator of new intellectual property opportunities. DProf Hutmacher is an internationally recognized leader in the fields of biomaterials, tissue engineering &regenerative medicine. He has translated a bone tissue engineering concept from the laboratory through to clinical application and ultimately FDA&CEMark clearance. More than 20000 patients have been treated with the FDA-cleared Polycaprolactone-based bone engineering scaffolds developed by Osteopore.
DProf Hutmacher is listed as one of the top 50 biomedical researchers in the world and a co-founder of Osteopore International. His most recent research efforts in applying additive biomanufacturing to scaffold-guided breast reconstruction have resulted in traditional scientific/academic outputs as well as pivotal commercialisation outcome.

Jan-Thorsten Schantz, MD, PhD
Clinical Advisor

Jan-Thorsten Schantz, MD, PhD

Until a tragic strike of fate left him severely incapacitated in early 2017, PD Dr. med. habil. Schantz was a world-leading clinician scientist in the area of tissue engineering & regenerative medicine. He had over 20 years of clinical experience in the field of plastic and reconstructive surgery, specifically in breast reconstructions and bone defects. PD Dr. Schantz is a co-founder of Osteopore, and his scientific and clinical work was pivotal for the regulatory approval of polycaprolactone-based bone scaffolds via the FDA 510(k) and CE certification pathways. PD Dr. Schantz wrote his medical doctoral thesis at Freiburg University, obtained his PhD at the National University of Singapore and his Habilitation in the field of tissue engineering/bone regeneration at TUM. His pre-eminent international standing and impact on the field is illustrated by his excellent publication record.
Until the abrupt end of his career due to permanent disability, PD Dr. Schantz also served as editor of the World Scientific book series 'Manuals in Biomedical Research' (since 2004), Visiting Associate Professor at Singapore's NTU School of Chemical and Biomedical Engineering (since 2013) and Acting Director of Clinical Research in Plastic and Reconstructive Surgery at Munich's Klinikum Rechts der Isar (since 2016).

Paul Severin Wiggenhauser, MD
Clinical Advisor

Paul Severin Wiggenhauser, MD

Dr. Wiggenhauser brings plastic surgical experience to BellaSeno through his residency in Plastic Surgery at Ludwig-Maximillian Universität München (Germany) and has dedicated his scientific work towards innovative CAD/CAM technologies and adipose derived stem cells to improve surgical techniques.
Dr. Wiggenhauser's thesis on Breast Tissue Engineering was awarded the Henner Graeff Preis for Best Thesis in Translational Research at Technische Universität München (Germany) in 2014. During his time at Ulm University Medical Centre, he has improved his analytical skills, strengthened his team work capacity and gained experience in management as vice coordinator of the central operation theatre at the Department of Oto-Rhino-Laryngology, Head and Neck Surgery. In 2017, he established a laboratory for stem cell research at Ludwig-Maximillian Universität München.
As deputy laboratory manager he focused on adipose tissue derived stem cells and translational research in plastic surgery. Moreover he investigated the application of 3D printing and polycaprolactone-based implants in reconstructive surgery. BellaSeno benefits from his experience in translational research in the field of plastic and reconstructive surgery. With his insight into daily clinical work, BellaSeno is able to optimize customer driven research and to improve implants with surgical insight.

Holger Buck, Dr.Jur

Holger Buck, Dr.Jur

Prof Buck serves as W3-Professor of International and German Business Law at a German University of Applied Sciences. He is member of the Scientific Committee of European Academy Otzenhausen and liaison professor of Heinrich Böll foundation. After having studied in Freiburg, Geneva and Strasbourg and after having graduated from Freiburg University he started his career as a lawyer while performing pro bono service as honorary judge (Anwaltsgericht). Prof. Buck works on international, EU and German competition law, sales law, company law as well as law of Intellectual Property. In recent years he has researched at University of Technology Sydney, University of British Columbia and University of Cape Town.

Our Investors and Funding Sources

BellaSeno has raised significant investments from a combination of private equity one of Germany’s top bioentrepreneurs as well as public grants from the Saxony Development Bank (SAB) and the European Fund for Regional Development (EFRE).

Herbert Stadler, PhD
Series A+B Investor

Herbert Stadler, PhD

Dr. Herbert Stadler is one of Europe's most successful serial bioentrepreneurs. Dr. Stadler has founded or co founded more than 10 companies including Stage Cell Therapies, IBA GmbH, Biometra GmbH, Ribonetics GmbH, HepaVec AG, IBA GmbH and DeveloGen AG. Dr. Stadler has successfully exited several startups - with the last exit being Stage GmbH sold to Juno/Celgene, now BMS.
Dr. Stadler obtained his Ph.D. at the Freie University of Berlin, obtained his postdoctoral lecture qualification ("Habilitation") at the University of Göttingen and headed the Molecular Neurobiology Group at the Max-Planck Institute of Biophysical Chemistry in Göttingen. He currently serves on the supervisory boards of BellaSeno GmbH, DeveloGen AG and IBA GmbH. .

Sächsische Aufbaubank

European Funds for Regional Development

Our Technology in the Media

The Senella® technology has been showcased multiple times in the media around the world.


Press Releases

Keep up to date with our company and technology.

Get in touch